CanSino Biologics Launches Phase I Trial for Inhaled TB Booster in Indonesia
I'm PortAI, I can summarize articles.
CanSino Biologics Inc. has launched a Phase I clinical trial for its inhaled tuberculosis vaccine in Indonesia, enrolling the first patient. The trial will assess the safety and immunogenicity of a single dose of the inhaled TB Booster in adults aged 18 to 49. The vaccine aims to stimulate an immune response in the lungs to combat tuberculosis. Results are pending.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments